Health,Stem Cells, and Technology

Saturday, March 2, 2013

S2RM Technology Versus iPSC, Parthenogenetic, And Other Stem Cell Therapeutic Technologies

The unique nature of the stem cell released molecules technology (SRM TechnologyTM) centers on the identification, selection, culture, and stimulation of the appropriate stem cells, and then the capture of those molecules released from the stem cells. In this manner, proprietary and patent-pending technology is used in the BioRegenerative Science (BRS) laboratory to capture what the stem cells normally release in the body. This is a systems based approach where, instead of a reductionist approach where one or two molecules are used for treatment, all of the molecules from the stem cells act together as they normally do in order to deliver the emergent properties of the system of all molecules. Further, BRS uses a technology that mimicks the manner in which the body heals itself whereby two or more types of stem cells become resident at the site of injury, and the two types of stem cells release their molecules into the tissue in concert, producing an emergent, synergistic healing effect. The use of two or more stem cell types to produce the SRM is known as BRS' S2RM Technology.TM
The S2RM Technology, exclusively used by BioRegenerative Sciences, has the advantage compared to other stem cell technologies of capturing a full and natural complement, or "system," of known molecules. This full complement of captured molecules from stem cells are subsequently injected into, or topically applied to, the patient in a precise dosing schedule to begin the systems-based regenerative process. Examples of topical S2RM TechnologyTM procedures include dry eye therapy, and lower extremity diabetic ulcer wound therapy where treatment is easily and most effectively delivered topically to the affected site. Injectable or ingestible S2RM TechnologyTMis used in procedures for Central Nervous System (CNS) and other organ diseases where the molecules cannot be delivered as a simple topical.
The BRS “Intelligent Molecules” Expression System employs a proprietary manufacturing process that allows the production of a wide variety of soluble and properly folded proteins and signaling molecules from multiple stem cell types important to immune modulation, and tissue repair and regeneration. The advantages of the process are in the production of biologically active proteins, exosomes, and signaling molecules, developing a “systems therapeutic” yielding a combination of many molecules, that act at multiple targets, resulting in a synergistic therapeutic with emergent therapeutic value. Furthermore, the production of the SRM (stem cell released molecules) does not require downstream solubilization, refolding, or other processes. Additionally, the process offers reduced purification requirements and lower production costs than other pharmacological and biological processes. The production of a therapeutic with a multitude of molecules represents a multi-targeted, systems biology approach to designing and manufacturing therapeutics. In the BRS “Intelligent Molecules” Expression System, multiple stem cell types are used to express SRM and thus the term “S2RMTM” is used to denote that two or more types of stem cells are used to produce a synergistic effect. The combination of stem cells used to develop each therapeutic depend on the condition being treated, and the type of tissue underlying the condition. Included in the S2RMTM is the BRS Exosome Delivery System that drives the active molecules through the layers of tissue into the target site, effectuating regeneration and repair in all damaged tissue regardless of the depth or remoteness of the target.
Unlike other so-called stem cell therapeutics, such as iPSCs and parthenogenetic stem cells, which are artificially induced "stem cells," and suffer from genetic and epigenetic programming errors, the adult stem cells in S2RMTM Technology are genetically and epigenetically normal. Further, the production of some "stem cell" therapeutics does not allow the molecules to be completely processed in the cell and allow for proper post-translational modifications. That is, the S2RMTM Technology allows the stem cells to fully process the molecules to the point of exosome production and release, including complete post-translational modification with resultant normal molecular folding characteristics and moiety construction. Other production techniques that are faster and less expensive, such as harsh cellular extraction methods with incomplete post-translational modification, result in incomplete molecules with errors such as 3-dimensional misfolding and moiety deletions, and cellular packaging errors. Thus, unlike iPSCs and parthenogenetic "stem cells" that don't produce the complete set of the natural molecules of a stem cell and also fail to complete the full assembly of each of the molecules, the true adult stem cells in S2RM Technology display correct genetic and epigenetic coding, with complete post-translational modifications and molecular packaging to produce a natural and full complement of molecules with complete post-translational modifications and hence full efficacy and a natural safety profile.

S2RM is a registered trademark of BRS, Inc.